We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
SENS Stock Up as Eversense 365 CGM Wins European CE Mark Approval
Read MoreHide Full Article
Key Takeaways
SENS shares gain 2.1% after securing European CE Mark approval for the Eversense 365 CGM.
Senseonics gains a one-year implantable CGM in Europe, expanding its addressable market beyond the U.S.
SENS holds full commercialization rights and integration potential, supporting revenue visibility.
Senseonics Holdings, Inc. (SENS - Free Report) recently scored a meaningful regulatory win in Europe, receiving CE Mark approval for its Eversense 365 continuous glucose monitoring (CGM) system.
The approval builds on the U.S. launch momentum of Eversense 365, the world’s first one-year CGM, and reinforces the company’s differentiation in the global CGM market. With full ownership of commercialization and growing integration opportunities with automated insulin delivery systems, Senseonics is positioning itself for steady top-line growth across both U.S. and European markets.
Likely Trend of SENS Stock Following the News
Following the announcement, shares of the company gained 2.1% in yesterday’s trading session. However, in the last six-month period, SENS’s shares have lost 29% compared with the industry’s 21.8% decline. The S&P 500 increased 12.3% in the same time frame.
The European approval of Eversense 365 meaningfully strengthens SENS’ long-term growth outlook by expanding its addressable market and creating a new, multi-year revenue stream outside the United States. A one-year implantable CGM clearly differentiates Senseonics in a crowded CGM landscape, supporting better pricing power, stronger patient retention and recurring procedure-driven demand.
As adoption scales across major EU markets and partnerships with insulin pump makers deepen, this approval should enhance revenue visibility, improve operating leverage and reinforce SENS’ competitive positioning in the global diabetes technology market.
Meanwhile, SENS currently has a market capitalization of $278.7 million.
Image Source: Zacks Investment Research
More on the Eversense 365 CGM System
Eversense 365 is designed to address some of the biggest pain points associated with traditional CGMs, starting with durability and reliability. It is the only CGM system with a full 365-day sensor, eliminating the need for frequent sensor changes and reducing the process to just one insertion, versus replacements every 10–14 days for short-term systems. The year-long sensor survivability also improves dependability, significantly reducing data gaps caused by sensor failures or routine changes. Since the tiny sensor sits securely under the skin, it cannot be accidentally knocked off, helping minimize wasted sensors, inconvenience and replacement costs for users.
Beyond longevity, the system emphasizes accuracy, comfort and flexibility, key drivers of long-term adoption. Eversense 365 delivers consistent accuracy over the full year with almost no false alerts from compression lows during sleep, increasing trust in glucose readings. Patient comfort is enhanced through a gentle, silicone-based adhesive that can be changed daily and causes minimal skin reactions.
The removable transmitter offers added freedom, allowing users to take it on and off without wasting a sensor or triggering a new warm-up period, while on-body vibration alerts ensure discreet notifications even when a phone is not nearby. Collectively, these features position Eversense 365 as a differentiated, patient-centric CGM solution with the potential to drive sustained adoption and engagement over time.
Favorable Industry Prospects for SENS
Per a report by Grand View Research, the global blood glucose monitoring devices market size was estimated at $15.53 billion in 2025 and is projected to reach $30.18 billion by 2033, expanding at a CAGR of 8.8% from 2026 to 2033.
The market is primarily influenced by the growing prevalence of diabetes and the increasing elderly population susceptible to conditions such as diabetes.
Other Recent Developments of SENS
Senseonics delivered a strong improvement in its third-quarter 2025 financial performance, with total revenue rising to $8.1 million from $4.3 million in the prior-year period, driven primarily by accelerating U.S. adoption. Also, U.S. revenue nearly tripled year over year to $6.4 million, reflecting improving commercial traction, while international revenue came in at $1.7 million, modestly lower than last year.
Importantly, the company reported a gross profit of $3.5 million in the quarter against a gross loss of $4.1 million a year ago, highlighting meaningful progress in cost structure, scale and overall operating efficiency.
Estimates for IDEXX’s 2025 earnings per share (EPS) have remained constant at $12.93 in the past 30 days. Shares of the company have risen 12.6% in the past year compared with the industry’s 11.1% growth. IDXX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.1%. In the last reported quarter, it delivered an earnings surprise of 8.3%.
Boston Scientific shares have gained 2.9% in the past year. Estimates for the company’s 2025 EPS have remained constant at $3.04 in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 7.4%. In the last reported quarter, it posted an earnings surprise of 5.6%.
STERIS shares have risen 9.1% in the past year. Estimates for the company’s 2025 EPS have increased by 2 cents to $10.23 in the past 30 days. STE’s earnings topped estimates in three of the trailing four quarters and matched on one occasion, delivering an average surprise of 2.6%. In the last reported quarter, it posted an earnings surprise of 2.6%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
SENS Stock Up as Eversense 365 CGM Wins European CE Mark Approval
Key Takeaways
Senseonics Holdings, Inc. (SENS - Free Report) recently scored a meaningful regulatory win in Europe, receiving CE Mark approval for its Eversense 365 continuous glucose monitoring (CGM) system.
The approval builds on the U.S. launch momentum of Eversense 365, the world’s first one-year CGM, and reinforces the company’s differentiation in the global CGM market. With full ownership of commercialization and growing integration opportunities with automated insulin delivery systems, Senseonics is positioning itself for steady top-line growth across both U.S. and European markets.
Likely Trend of SENS Stock Following the News
Following the announcement, shares of the company gained 2.1% in yesterday’s trading session. However, in the last six-month period, SENS’s shares have lost 29% compared with the industry’s 21.8% decline. The S&P 500 increased 12.3% in the same time frame.
The European approval of Eversense 365 meaningfully strengthens SENS’ long-term growth outlook by expanding its addressable market and creating a new, multi-year revenue stream outside the United States. A one-year implantable CGM clearly differentiates Senseonics in a crowded CGM landscape, supporting better pricing power, stronger patient retention and recurring procedure-driven demand.
As adoption scales across major EU markets and partnerships with insulin pump makers deepen, this approval should enhance revenue visibility, improve operating leverage and reinforce SENS’ competitive positioning in the global diabetes technology market.
Meanwhile, SENS currently has a market capitalization of $278.7 million.
Image Source: Zacks Investment Research
More on the Eversense 365 CGM System
Eversense 365 is designed to address some of the biggest pain points associated with traditional CGMs, starting with durability and reliability. It is the only CGM system with a full 365-day sensor, eliminating the need for frequent sensor changes and reducing the process to just one insertion, versus replacements every 10–14 days for short-term systems. The year-long sensor survivability also improves dependability, significantly reducing data gaps caused by sensor failures or routine changes. Since the tiny sensor sits securely under the skin, it cannot be accidentally knocked off, helping minimize wasted sensors, inconvenience and replacement costs for users.
Beyond longevity, the system emphasizes accuracy, comfort and flexibility, key drivers of long-term adoption. Eversense 365 delivers consistent accuracy over the full year with almost no false alerts from compression lows during sleep, increasing trust in glucose readings. Patient comfort is enhanced through a gentle, silicone-based adhesive that can be changed daily and causes minimal skin reactions.
The removable transmitter offers added freedom, allowing users to take it on and off without wasting a sensor or triggering a new warm-up period, while on-body vibration alerts ensure discreet notifications even when a phone is not nearby. Collectively, these features position Eversense 365 as a differentiated, patient-centric CGM solution with the potential to drive sustained adoption and engagement over time.
Favorable Industry Prospects for SENS
Per a report by Grand View Research, the global blood glucose monitoring devices market size was estimated at $15.53 billion in 2025 and is projected to reach $30.18 billion by 2033, expanding at a CAGR of 8.8% from 2026 to 2033.
The market is primarily influenced by the growing prevalence of diabetes and the increasing elderly population susceptible to conditions such as diabetes.
Other Recent Developments of SENS
Senseonics delivered a strong improvement in its third-quarter 2025 financial performance, with total revenue rising to $8.1 million from $4.3 million in the prior-year period, driven primarily by accelerating U.S. adoption. Also, U.S. revenue nearly tripled year over year to $6.4 million, reflecting improving commercial traction, while international revenue came in at $1.7 million, modestly lower than last year.
Importantly, the company reported a gross profit of $3.5 million in the quarter against a gross loss of $4.1 million a year ago, highlighting meaningful progress in cost structure, scale and overall operating efficiency.
SENS’s Zacks Rank & Stocks to Consider
SENS carries a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks in the broader medical space are IDEXX Laboratories (IDXX - Free Report) , Boston Scientific (BSX - Free Report) and STERIS (STE - Free Report) . Each stock presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Estimates for IDEXX’s 2025 earnings per share (EPS) have remained constant at $12.93 in the past 30 days. Shares of the company have risen 12.6% in the past year compared with the industry’s 11.1% growth. IDXX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.1%. In the last reported quarter, it delivered an earnings surprise of 8.3%.
Boston Scientific shares have gained 2.9% in the past year. Estimates for the company’s 2025 EPS have remained constant at $3.04 in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 7.4%. In the last reported quarter, it posted an earnings surprise of 5.6%.
STERIS shares have risen 9.1% in the past year. Estimates for the company’s 2025 EPS have increased by 2 cents to $10.23 in the past 30 days. STE’s earnings topped estimates in three of the trailing four quarters and matched on one occasion, delivering an average surprise of 2.6%. In the last reported quarter, it posted an earnings surprise of 2.6%.